Drug intelligence / Profile preview

TPC-002

Development stage: Preclinical
Lead developer: Cothera Bioscience
Modality: Small Molecules

Overview

TPC-002 is a preclinical drug candidate being developed by Tetra Pharm Technologies, a Danish pharmaceutical company focused on the endocannabinoid system (ECS). The compound is currently being evaluated for its potential in treating anxiety and "Overall Syndrome." Tetra Pharm Technologies specializes in utilizing advanced drug delivery systems to optimize the therapeutic profile of cannabinoid-based medicines. TPC-002 is part of the company's TPC series of compounds, which are currently in the discovery and pre-clinical phases of development.

Beyond the preview

Go deeper on TPC-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPC-002.

Explore the full profile